Lamzede® (velmanase alfa-tycv)

Lamzede (velmanase alfa‑tycv) is covered for treatment of non‑central nervous system manifestations of alpha‑mannosidosis in adults and children but is excluded for CNS‑only disease or uses outside the FDA‑approved indication. Coverage requires alpha‑mannosidase activity <10% in blood leukocytes, genetic confirmation of biallelic pathogenic MAN2B1 variants, documentation of non‑CNS manifestations, prescription or consult with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, dosing at 1 mg/kg IV weekly, and is authorized for up to 12 months.

"Treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients (FDA-approved indication)."

Sign up to see full coverage criteria, indications, and limitations.